Congenital arterial malformation – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Thu, 28 May 2026 11:26:12 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Congenital arterial malformation – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study on Sirolimus and Prednisolone for Treating Superficial Arteriovenous Malformations in Patients https://clinicaltrials.eu/trial/study-on-sirolimus-and-prednisolone-for-treating-superficial-arteriovenous-malformations-in-patients/ Wed, 29 Apr 2026 15:03:07 +0000 https://clinicaltrials.eu/trial/study-on-sirolimus-and-prednisolone-for-treating-superficial-arteriovenous-malformations-in-patients/ This clinical trial is focused on studying the effectiveness of a medication called sirolimus, which is marketed under the name Rapamune, in treating a condition known as superficial arteriovenous malformations. These malformations are abnormal connections between arteries and veins that can cause various symptoms and complications. The purpose of the study is to evaluate whether sirolimus can help reduce the size of these malformations.

Participants in the study will take sirolimus in the form of coated tablets. The study will also involve the use of another medication, prednisolone metasulfobenzoate sodium, which is available as an orodispersible tablet under the name SOLUPRED. The study will compare the effects of sirolimus with those of a placebo to determine its effectiveness. The main goal is to see if there is a reduction in the size of the malformations over the course of the study.

The study will take place over a period of time, with assessments at various intervals to monitor changes in the malformations. Participants will be observed for any changes in the size of the malformations, and the results will be analyzed to determine the effectiveness of the treatment. The study aims to provide valuable information on the potential benefits of sirolimus for individuals with superficial arteriovenous malformations.

]]>